ライフサイエンスコーパス: intensive insulin therapy

1 or a minimum of 12 months who were receiving intensive insulin therapy.

2 ll pregnant women with type 1 diabetes using intensive insulin therapy.

3 nsulin therapy as compared with a decline in intensive insulin therapy.

4 rrection uncovers occult hypoglycemia during intensive insulin therapy.

5 educes the prevalence of hypoglycemia during intensive insulin therapy.

6 rom recurrent hypoglycemia in patients using intensive insulin therapy.

7 re from critically ill patients who received intensive insulin therapy.

8 r breakdown, that follows the institution of intensive insulin therapy.

9 rregulation seen in diabetic patients during intensive insulin therapy.

10 as a basal insulin to increase the safety of intensive insulin therapy.

11 orable outcome, which enhances the safety of intensive insulin therapy.

12 answer to the question about the effects of intensive insulin therapy.

13 de-1 (1.5 pmol/kg/min) or normal saline plus intensive insulin therapy.

14 ation of palmitate significantly improved in intensive insulin therapy (0.9 +/- 0.1 to 1.7 +/- 0.1 mi

15 ose release was significantly greater in the intensive insulin therapy after treatment compared with

16 n more efficacious, at least initially, with intensive insulin therapy and may justify setting a high

17 ic porcine islets could be an alternative to intensive insulin therapy and pancreatic transplantation

18 The rationale for intensive insulin therapy and results from major clinica

19 However, the extent to which intensive insulin therapy and tight control of blood glu

20 into two groups receiving either standard or intensive insulin therapy and were followed for 27 month

21 irected therapy, drotrecogin alfa, steroids, intensive insulin therapy, and lung-protective ventilati

22 Intensive insulin therapy, and specifically insulin pump

23 r breakdown is markedly increased with acute intensive insulin therapy but can be reversed by treatin

24 tive glycemic control could be achieved with intensive insulin therapy, but no effect on vascular end

25 Muscle atrophy was not ameliorated by intensive insulin therapy, but possibly aggravated by co

26 Clinical studies have demonstrated that intensive insulin therapy causes a transient worsening o

27 wer plasma glucose levels, particularly with intensive insulin therapy, could therefore be harmful.

28 (HbA(1c) 10.1%) and again after 3 months of intensive insulin therapy designed to produce near-normo

29 Intensive insulin therapy displayed a significantly high

30 Intensive insulin therapy during cardiac surgery does no

31 Tight glycemic control by intensive insulin therapy effectively delays the onset a

32 Intensive insulin therapy for tight glycemic control in

33 oglycemia is the most feared complication of intensive insulin therapy for type 1 diabetes.

34 s needed to assess the benefit:risk ratio of intensive insulin therapy for type II diabetic patients

35 Intensive insulin therapy has improved outcomes in some,

36 Despite demonstrated benefits, intensive insulin therapy has not gained widespread clin

37 0 mg/dl) improves patient survival; however, intensive insulin therapy (IIT) targeting normal blood g

38 The benefits and harms of intensive insulin therapy (IIT) titrated to strict glyce

39 tive Study explored the feasibility of using intensive insulin therapy in 153 male type II diabetic p

40 Hypoglycemia occurs frequently during intensive insulin therapy in patients with both type 1 a

41 Intensive insulin therapy in the critically ill reduces

42 The reduced mortality observed with intensive insulin therapy in the Leuven trials cannot be

43 inical problem is the question of the use of intensive insulin therapy in type II diabetic individual

44 Acute intensive insulin therapy is an independent risk factor

45 has been shown to reduce mortality; however, intensive insulin therapy is associated with iatrogenic

46 al antibiotics, early goal-directed therapy, intensive insulin therapy, lung-protective ventilation,

47 Intensive insulin therapy maintained blood glucose level

48 Here we demonstrate that acute intensive insulin therapy markedly increases VEGF mRNA a

49 Early data from the UKPDS also suggest that intensive insulin therapy may be more effective in lower

50 Intensive insulin therapy may cause a transient worsenin

51 Intensive insulin therapy may impair cerebral glucose me

52 oose insulin (n=33) for the initial 2 yrs or intensive insulin therapy (n=14) for the last year.

53 Intensive insulin therapy normalizes glycemia by decreas

54 We evaluated the effects of prior intensive insulin therapy on the prevalence and incidenc

55 insulin therapy vs. 6.8 +/- 0.9 mg/kg x min intensive insulin therapy; p = .5).

56 together, these findings indicate that acute intensive insulin therapy produces a transient worsening

57 Intensive insulin therapy promises to reduce health risk

58 lood glucose levels < or =120 mg/dL using an intensive insulin therapy protocol improves insulin sens

59 Intensive insulin therapy results in a net reduction in

60 Intensive insulin therapy significantly lowered mean blo

61 The Leuven intensive insulin therapy strategy increased mean daily

62 Intensive insulin therapy (systemic glucose target: 4.4-

63 , patients were randomized to receive either intensive insulin therapy (targeting normoglycemia, betw

64 s more likely to produce hypoglycemia during intensive insulin therapy than is total parenteral nutri

65 In 14 patients treated with intensive insulin therapy, there was a reduction in micr

66 the evidence for the link between the use of intensive insulin therapy to achieve different glycemic

67 RECOMMENDATION 2: ACP recommends not using intensive insulin therapy to normalize blood glucose in

68 Intensive insulin therapy to normalize blood glucose may

69 xperts calling for routine administration of intensive insulin therapy to normalize glucose levels in

70 RECOMMENDATION 1: ACP recommends not using intensive insulin therapy to strictly control blood gluc

71 amp infusion rate posttreatment (9.1 +/- 1.3 intensive insulin therapy versus 4.8 +/- 0.6 mg/kg x min

72 py (5.0 +/- 0.9 vs. 2.5 +/- 0.6 mg/kg x min; intensive insulin therapy vs. conventional insulin thera

73 However, intensive insulin therapy was associated with increased

74 Intensive insulin therapy was done using a stepwise appr

75 nd Complications Trial (DCCT) has shown that intensive insulin therapy will prevent or delay the onse

76 Intensive insulin therapy with IIP and MDI is effective

77 nduction, islet culture, heparinization, and intensive insulin therapy with the same low-dose tacroli

78 Intensive insulin therapy with tight glycaemic control h

79 nuous infusion of glucagon-like peptide-1 to intensive insulin therapy would result in better glucose